Quantum Biopharma Ltd. (NASDAQ:QNTM) Short Interest Down 23.0% in February

Quantum Biopharma Ltd. (NASDAQ:QNTM) was the recipient of a large drop in short interest during the month of February. As of February 27th, there was short interest totaling 83,550 shares, a drop of 23.0% from the February 12th total of 108,439 shares. Approximately 2.4% of the shares of the company are sold short. Based on an average daily trading volume, of 33,437 shares, the days-to-cover ratio is presently 2.5 days. Based on an average daily trading volume, of 33,437 shares, the days-to-cover ratio is presently 2.5 days. Approximately 2.4% of the shares of the company are sold short.

Analyst Ratings Changes

QNTM has been the subject of a number of research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Quantum Biopharma in a research note on Monday, December 29th. Wall Street Zen lowered shares of Quantum Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, January 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Quantum Biopharma Price Performance

Shares of NASDAQ:QNTM traded down $0.08 on Friday, reaching $2.48. The company’s stock had a trading volume of 278,535 shares, compared to its average volume of 259,845. Quantum Biopharma has a 52-week low of $2.07 and a 52-week high of $38.25. The stock has a market capitalization of $9.47 million, a P/E ratio of -0.23 and a beta of 0.33. The stock’s 50-day moving average is $4.74 and its two-hundred day moving average is $9.62.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Jane Street Group LLC acquired a new position in shares of Quantum Biopharma in the fourth quarter valued at approximately $80,000. Virtu Financial LLC acquired a new stake in shares of Quantum Biopharma during the fourth quarter worth $76,000. Finally, Steward Partners Investment Advisory LLC acquired a new stake in shares of Quantum Biopharma during the second quarter worth $63,000. 1.24% of the stock is currently owned by hedge funds and other institutional investors.

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.